Knockdown of lncRNA TP53TG1 Enhances the Efficacy of Sorafenib in Human Hepatocellular Carcinoma Cells
The multikinase inhibitor, sorafenib, is a first-line treatment for hepatocellular carcinoma (HCC), but its limited efficacy, drug resistance and toxicity are a concern. In this study, we investigated the role of lncRNA TP53TG1 in the efficacy of sorafenib in HCC cells. We found that treatment with...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Non-Coding RNA |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2311-553X/8/4/61 |
| _version_ | 1827598813783654400 |
|---|---|
| author | Qingchun Lu Mingyang Xin Qian Guo Brad S. Rothberg Ana M. Gamero Ling Yang |
| author_facet | Qingchun Lu Mingyang Xin Qian Guo Brad S. Rothberg Ana M. Gamero Ling Yang |
| author_sort | Qingchun Lu |
| collection | DOAJ |
| description | The multikinase inhibitor, sorafenib, is a first-line treatment for hepatocellular carcinoma (HCC), but its limited efficacy, drug resistance and toxicity are a concern. In this study, we investigated the role of lncRNA TP53TG1 in the efficacy of sorafenib in HCC cells. We found that treatment with sorafenib increased the expression of TP53TG1 in HCC cells. Knockdown of TP53TG1 sensitized tumor cells to the antiproliferative effects of sorafenib. Furthermore, TP53TG1 knockdown had an additive inhibitory effect on HCC cell proliferation and migration in the presence of sorafenib. The combination of TP53TG1 knockdown and sorafenib drastically inhibited the activation of the ERK pathway. This work demonstrates that TP53TG1 deficiency enhances the efficacy of sorafenib in HCC. Combining TP53TG1 knockdown with sorafenib may be an optimal form of therapy for HCC treatment. |
| first_indexed | 2024-03-09T04:00:15Z |
| format | Article |
| id | doaj.art-39d9801afe23443895052ee6c53c4a2b |
| institution | Directory Open Access Journal |
| issn | 2311-553X |
| language | English |
| last_indexed | 2024-03-09T04:00:15Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Non-Coding RNA |
| spelling | doaj.art-39d9801afe23443895052ee6c53c4a2b2023-12-03T14:13:43ZengMDPI AGNon-Coding RNA2311-553X2022-08-01846110.3390/ncrna8040061Knockdown of lncRNA TP53TG1 Enhances the Efficacy of Sorafenib in Human Hepatocellular Carcinoma CellsQingchun Lu0Mingyang Xin1Qian Guo2Brad S. Rothberg3Ana M. Gamero4Ling Yang5Department of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USADepartment of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USADepartment of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USADepartment of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USADepartment of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USADepartment of Medical Genetics and Molecular Biochemistry, Lewis Katz School of Medicine at Temple University, Philadelphia, PA 19140, USAThe multikinase inhibitor, sorafenib, is a first-line treatment for hepatocellular carcinoma (HCC), but its limited efficacy, drug resistance and toxicity are a concern. In this study, we investigated the role of lncRNA TP53TG1 in the efficacy of sorafenib in HCC cells. We found that treatment with sorafenib increased the expression of TP53TG1 in HCC cells. Knockdown of TP53TG1 sensitized tumor cells to the antiproliferative effects of sorafenib. Furthermore, TP53TG1 knockdown had an additive inhibitory effect on HCC cell proliferation and migration in the presence of sorafenib. The combination of TP53TG1 knockdown and sorafenib drastically inhibited the activation of the ERK pathway. This work demonstrates that TP53TG1 deficiency enhances the efficacy of sorafenib in HCC. Combining TP53TG1 knockdown with sorafenib may be an optimal form of therapy for HCC treatment.https://www.mdpi.com/2311-553X/8/4/61long non-coding RNATP53TG1sorafenibhepatocellular carcinomaefficacy |
| spellingShingle | Qingchun Lu Mingyang Xin Qian Guo Brad S. Rothberg Ana M. Gamero Ling Yang Knockdown of lncRNA TP53TG1 Enhances the Efficacy of Sorafenib in Human Hepatocellular Carcinoma Cells Non-Coding RNA long non-coding RNA TP53TG1 sorafenib hepatocellular carcinoma efficacy |
| title | Knockdown of lncRNA TP53TG1 Enhances the Efficacy of Sorafenib in Human Hepatocellular Carcinoma Cells |
| title_full | Knockdown of lncRNA TP53TG1 Enhances the Efficacy of Sorafenib in Human Hepatocellular Carcinoma Cells |
| title_fullStr | Knockdown of lncRNA TP53TG1 Enhances the Efficacy of Sorafenib in Human Hepatocellular Carcinoma Cells |
| title_full_unstemmed | Knockdown of lncRNA TP53TG1 Enhances the Efficacy of Sorafenib in Human Hepatocellular Carcinoma Cells |
| title_short | Knockdown of lncRNA TP53TG1 Enhances the Efficacy of Sorafenib in Human Hepatocellular Carcinoma Cells |
| title_sort | knockdown of lncrna tp53tg1 enhances the efficacy of sorafenib in human hepatocellular carcinoma cells |
| topic | long non-coding RNA TP53TG1 sorafenib hepatocellular carcinoma efficacy |
| url | https://www.mdpi.com/2311-553X/8/4/61 |
| work_keys_str_mv | AT qingchunlu knockdownoflncrnatp53tg1enhancestheefficacyofsorafenibinhumanhepatocellularcarcinomacells AT mingyangxin knockdownoflncrnatp53tg1enhancestheefficacyofsorafenibinhumanhepatocellularcarcinomacells AT qianguo knockdownoflncrnatp53tg1enhancestheefficacyofsorafenibinhumanhepatocellularcarcinomacells AT bradsrothberg knockdownoflncrnatp53tg1enhancestheefficacyofsorafenibinhumanhepatocellularcarcinomacells AT anamgamero knockdownoflncrnatp53tg1enhancestheefficacyofsorafenibinhumanhepatocellularcarcinomacells AT lingyang knockdownoflncrnatp53tg1enhancestheefficacyofsorafenibinhumanhepatocellularcarcinomacells |